Pfizer licenses Chinese cancer drug

semafor.com/article/05/20/2025/pfizer-licenses-chinese-cancer-drug

The News
Pfizer licensed a new Chinese cancer drug for $1.25 billion, a sign of Chinese biotech’s steady move from imitator to innovator.
The treatment, made by Shenyang-based 3SBio, is being tested on several tumor types: The company’s shares leapt 52% on the deal, which it hopes will…

This story appeared on semafor.com, 2025-05-20 11:03:02.
The Entire Business World on a Single Page. Free to Use →